June 2022 - Press Release: 4D Lifetec announces successful first closing of CHF 1.9 million Series B financing to launch its early lung cancer detection liquid biopsy assay 4D Lifetest™ Lung Dx in Europe.



11.07.2022, CHAM. The currently launched 4D Lifetest™ Lung Dx is the first non-invasive CE-IVD blood liquid biopsy assay to assess lung cancer formation at its earliest stage. This diagnostic information is a breakthrough progress to tackle the catastrophic mortality rates of lung cancer patients and protect benign patients from the invasive stress of frequently repeated surveillance diagnostics.


4D Lifetec AG, a privately-held Swiss diagnostics company focusing on the development and marketing of early stage liquid biopsy cancer diagnostics, announced today that it has raised CHF 1.9 million in a first closing of its Series B round. This first closing was fully supported by both existing and new investors as well as from strategic partners. 4D Lifetec intends to complete the Series B investment round by the end of 2022.


To read the press release click here.